China NT Pharma Group Company Limited (1011.HK)
HKD 0.41
(-7.87%)
HKD 0.41
(-7.87%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.36 Million CNY | -45.92% |
| 2022 | 117.55 Million CNY | -48.53% |
| 2021 | 228.39 Million CNY | 4.85% |
| 2020 | 217.82 Million CNY | -14.51% |
| 2019 | 254.8 Million CNY | -29.51% |
| 2018 | 361.48 Million CNY | 57.68% |
| 2017 | 229.25 Million CNY | -25.76% |
| 2016 | 308.78 Million CNY | 5.26% |
| 2015 | 293.36 Million CNY | -14.35% |
| 2014 | 342.51 Million CNY | -26.25% |
| 2013 | 464.4 Million CNY | -34.31% |
| 2012 | 706.99 Million CNY | 34.64% |
| 2011 | 525.09 Million CNY | 28.8% |
| 2010 | 407.66 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 7.1 Million CNY | 0.0% |
| 2023 Q2 | 10.1 Million CNY | 0.0% |
| 2023 FY | 63.57 Million CNY | -45.92% |
| 2022 Q4 | 40.57 Million CNY | 0.0% |
| 2022 Q2 | 67.29 Million CNY | 0.0% |
| 2022 FY | 117.55 Million CNY | -48.53% |
| 2021 FY | 228.39 Million CNY | 4.85% |
| 2021 Q4 | 162.16 Million CNY | 0.0% |
| 2021 Q2 | 43.55 Million CNY | 0.0% |
| 2020 Q2 | 79.15 Million CNY | 0.0% |
| 2020 FY | 217.82 Million CNY | -14.51% |
| 2019 FY | 254.8 Million CNY | -29.51% |
| 2019 Q2 | 85.37 Million CNY | 0.0% |
| 2018 FY | 361.48 Million CNY | 57.68% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 Q2 | 99.85 Million CNY | 0.0% |
| 2017 Q2 | 88.15 Million CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 FY | 229.25 Million CNY | -25.76% |
| 2016 Q2 | 98.63 Million CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 FY | 308.78 Million CNY | 5.26% |
| 2015 FY | 293.36 Million CNY | -14.35% |
| 2015 Q2 | 124 Million CNY | 0.0% |
| 2015 Q4 | 205.87 Million CNY | 0.0% |
| 2014 Q4 | 181.99 Million CNY | 0.0% |
| 2014 FY | 342.51 Million CNY | -26.25% |
| 2014 Q2 | 135.04 Million CNY | 0.0% |
| 2013 Q4 | 268.89 Million CNY | 0.0% |
| 2013 FY | 464.4 Million CNY | -34.31% |
| 2013 Q2 | 624.55 Million CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 FY | 706.99 Million CNY | 34.64% |
| 2012 Q4 | - CNY | 0.0% |
| 2011 FY | 525.09 Million CNY | 28.8% |
| 2011 Q4 | - CNY | 0.0% |
| 2011 Q2 | - CNY | 0.0% |
| 2010 FY | 407.66 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | 69.841% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 99.809% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | 79.266% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | 97.919% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | 56.929% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | 98.754% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 99.401% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | 98.537% |
| PuraPharm Corporation Limited | 216.62 Million HKD | 96.6% |
| SSY Group Limited | 1.98 Billion HKD | 99.628% |
| JBM (Healthcare) Limited | 163.87 Million HKD | 95.505% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | 97.437% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 99.975% |